Analyst Price Targets — KTTA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 8, 2025 11:11 am | Sara Nik | H.C. Wainwright | $3.00 | $1.13 | TheFly | Pasithea Therapeutics initiated with a Buy at H.C. Wainwright |
Latest News for KTTA
Pasithea Therapeutics (NASDAQ: KTTA - Get Free Report) is projected to announce its results before the market opens on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Pasithea Therapeutics Trading Down 0.9% Shares of KTTA stock opened at $0.82 on Monday. The stock has a market cap
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Pasithea Therapeutics (Nasdaq: KTTA) will present to Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 25, 2026, 4:00 PM ET
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), today provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KTTA.
U.S. House Trading
No House trades found for KTTA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.